Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


First published online March 29, 2007
OPEN ACCESS ARTICLE
This Article
Free via Open Access: OA
Right arrow Full Text (PDF)
Right arrowOA All Versions of this Article:
2007-0127v1
25/7/1603    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mannello, F.
Right arrow Articles by Tonti, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mannello, F.
Right arrow Articles by Tonti, G. A.
Submitted on February 15, 2007
Accepted on March 20, 2007

Translational and Clinical Research

No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer or feeder-free; medium with foetal calf serum, human serum or enriched plasma; serum-free, serum replacement nonconditioned medium or ad-hoc formula? All that glitters is not gold!

Ferdinando Mannello 1* and Gaetana A. Tonti 1

1 Institute of Histology and Laboratory Analysis, University "Carlo Bo", Urbino, Italy

* To whom correspondence should be addressed. E-mail: f.mannello{at}uniurb.it.


   Abstract

The choice of an optimal strategy of stem cell culture is at the moment an impossible task, and the elaboration of a culture medium adapted to the production of embryonic and adult mesenchymal stem cells for the clinical application of cell therapy remains a crucial matter. To make an informed choice, it is crucial to not underestimate the theoretical health risk of using xenogenic compounds, to limit the immunological reactions once stem cells are transplanted, to not overestimate the controversial results obtained with human serum, plasma and blood derivatives, as well as to carefully examine the pros and cons of serum-free and ad-hoc formulation strategies; besides that, to also maintain multipotentiality, self-renewal and transplantability. The extent to which we are able to achieve effective cell therapies will depend on assimilating a rapidly developing base of scientific knowledge with the practical considerations of design, delivery, and host response. Although clinical studies have already started, many questions remain unsolved, and concomitantly even more evidence on suitable and safe off-the-shelf products (mainly xeno-free) for embryonic and mesenchymal stem cells are cropping up, even though there should be no rush to enter the clinical stage while the underlying basic research is still not so solid: this solely will lead to high quality translational research, without making blunders stemming from the assumption that all that glitters is not gold.

Key Words. Mesenchymal stem cells, Embryonic stem cells, Foetal calf serum, Serum-free medium, Autologous human serum, Heterologous human serum, Platelet-factor rich supernatant




This article has been cited by other articles:


Home page
Stem CellsHome page
G. M. Hoben, E. J. Koay, and K. A. Athanasiou
Fibrochondrogenesis in Two Embryonic Stem Cell Lines: Effects of Differentiation Timelines
Stem Cells, February 1, 2008; 26(2): 422 - 430.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
M. Hisamatsu-Sakamoto, N. Sakamoto, and A. S. Rosenberg
Embryonic Stem Cells Cultured in Serum-Free Medium Acquire Bovine Apolipoprotein B-100 from Feeder Cell Layers and Serum Replacement Medium
Stem Cells, January 1, 2008; 26(1): 72 - 78.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.stemcellsportal.com/
Copyright © 2007 by AlphaMed Press.